Emcure Pharmaceuticals

Emcure Pharmaceuticals, is an Indian pharmaceutical company headquartered in Pune, Maharashtra. Emcure's product portfolio includes tablets, capsules (both softgel capsules and hard-gel capsules), and injectables.
US plant.
USA - The company has a manufacturing facility and R&D center in East Brunswick, New Jersey, USA.
Capital markets.
Emcure is planning to raise money through an initial public offering for some time now In 2014, Blackstone sold its stake in Emcure to Bain Capital
Recalls.
In 2010, Pfizer had to recall three batches of an anti-bacterial product from the US market due to presence of "Bacillus anthracis", "Penicillium chrysogenum" & "E. coli" in some samples. Teva recalled several batches of two products due to white tablets showing presence of "Yersinia pestis" in 2011.
AIDS Initiative.
Emcure voices its concerns on HIV/AIDS through its "Let's fight AIDS together" initiative and supplies Antiretroviral drugs to Africa, Asia Pacific and CIS. As a part of its corporate social responsibility it supports 'Taal', a pharmacy for HIV/AIDS patients run by HIV/AIDS patients.
Emcure has license agreements with Bristol-Myers Squibb for Atazanavir and Gilead Sciences for Tenofovir as part of their Global Access Programs.
Anticancer portfolio.
Roche has signed a deal with Emcure for manufacturing its blockbuster anticancer drugs Herceptin and Mabthera in India. Under this programme the cancer drugs shall be made available to the developing world at an affordable 'cut-price' version.
Price fixing.
Heritage Pharmaceuticals, a division of Emcure has entered into a deferred prosecution agreement with the United States Department of Justice, Antitrust Division ("DOJ") relating to a one-count Information for a conspiracy involving glyburide. In conjunction with the DPA, Heritage will pay a $225,000 fine.
In addition, the Company separately agreed to a settlement with the United States Department of Justice, Civil Division to resolve potential civil liability under the False Claims Act in connection with the antitrust conduct. Under the terms of the settlement, the Company has agreed to pay $7.1 million. 
Heritage has agreed to pay $7.1 million as part of a settlement with DOJ's Civil Division to resolve allegations of selling drugs at the artificially inflated prices, which resulted in claims submitted to or purchases by federal healthcare programs